TY - JOUR
T1 - Association between Multimorbidity and COVID-19 Mortality in Qatar
T2 - A Cross-Sectional Study
AU - AbouGalala, Khalid
AU - Elsayed, Basant
AU - Elmarasi, Mohamed
AU - Kotob, Mona
AU - Taha, Reham
AU - Abbasher, Fardous
AU - Amarah, Ahmed
AU - El Hamawi, Mariam
AU - Albayat, Soha S.
AU - Abdulmajeed, Jazeel
AU - Sallam, Mohamed A.H.
AU - Al-Shamali, Maha H.M.
AU - Al-Romaihi, Hamad E.
AU - Bansal, Devendra
AU - Musa, Omran A.H.
AU - Farag, Elmoubasher
AU - Al-Thani, Mohammed H.J.
AU - Chivese, Tawanda
AU - Emara, Mohamed M.
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2023/3
Y1 - 2023/3
N2 - This study assessed the association between multimorbidity and mortality from COVID-19 in the Middle East and North Africa region, where such data are scarce. We conducted a cross-sectional study using data of all cases with COVID-19 reported to the Ministry of Public Health of Qatar from March to September 2020. Data on pre-existing comorbidities were collected using a questionnaire and multimorbidity was defined as having at least two comorbidities. Proportions of deaths were compared by comorbidity and multimorbidity status and multivariable logistic regression analyses were carried out. A total of 92,426 participants with a mean age of 37.0 years (SD 11.0) were included. Mortality due to COVID-19 was associated with gastrointestinal diseases (aOR 3.1, 95% CI 1.16–8.30), respiratory diseases (aOR 2.9, 95% CI 1.57–5.26), neurological diseases (aOR 2.6, 95% CI 1.19–5.54), diabetes (aOR 1.8, 95% CI 1.24–2.61), and CVD (aOR 1.5, 95% CI 1.03–2.22). COVID-19 mortality was strongly associated with increasing multimorbidity; one comorbidity (aOR 2.0, 95% CI 1.28–3.12), two comorbidities (aOR 2.8, 95% CI 1.79–4.38), three comorbidities (aOR 6.0, 95% 3.34–10.86) and four or more comorbidities (aOR 4.15, 95% 1.3–12.88). This study demonstrates a strong association between COVID-19 mortality and multimorbidity in Qatar.
AB - This study assessed the association between multimorbidity and mortality from COVID-19 in the Middle East and North Africa region, where such data are scarce. We conducted a cross-sectional study using data of all cases with COVID-19 reported to the Ministry of Public Health of Qatar from March to September 2020. Data on pre-existing comorbidities were collected using a questionnaire and multimorbidity was defined as having at least two comorbidities. Proportions of deaths were compared by comorbidity and multimorbidity status and multivariable logistic regression analyses were carried out. A total of 92,426 participants with a mean age of 37.0 years (SD 11.0) were included. Mortality due to COVID-19 was associated with gastrointestinal diseases (aOR 3.1, 95% CI 1.16–8.30), respiratory diseases (aOR 2.9, 95% CI 1.57–5.26), neurological diseases (aOR 2.6, 95% CI 1.19–5.54), diabetes (aOR 1.8, 95% CI 1.24–2.61), and CVD (aOR 1.5, 95% CI 1.03–2.22). COVID-19 mortality was strongly associated with increasing multimorbidity; one comorbidity (aOR 2.0, 95% CI 1.28–3.12), two comorbidities (aOR 2.8, 95% CI 1.79–4.38), three comorbidities (aOR 6.0, 95% 3.34–10.86) and four or more comorbidities (aOR 4.15, 95% 1.3–12.88). This study demonstrates a strong association between COVID-19 mortality and multimorbidity in Qatar.
KW - chronic diseases
KW - comorbidities
KW - COVID-19
KW - Middle East and North Africa
KW - mortality
KW - multimorbidity
KW - pre-existing diseases
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85150946478&partnerID=8YFLogxK
U2 - 10.3390/microbiolres14010023
DO - 10.3390/microbiolres14010023
M3 - Article
AN - SCOPUS:85150946478
SN - 2036-7473
VL - 14
SP - 289
EP - 296
JO - Microbiology Research
JF - Microbiology Research
IS - 1
ER -